¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cellular immunity deficiency syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
¿µ¹® Klinefelter syndrome ÇÑ±Û Å¬¶óÀÎÆçÅÍÁõÈıº
¼³¸í   
  1942³â H.F. Å¬¶óÀÎÆçÅͰ¡ ±âÀçÇÑ ¼º¿°»öüÀÌ»óÁõÈıº. Á¤»óÀÎÀÇ ¼º¿°»öüÇüÀº ³²¼º XY, ¿©¼º XX¸¦ ³ªÅ¸³»Áö¸¸, ÀÌ ÁõÈıº¿¡¼­´Â ¼º¿°»öüÇüÀÌ XXY. XXYY, XXXXY µîÀÇ ¿©·¯ °¡Áö ÀÌ»óÇÑ ÇüŸ¦ ³ªÅ¸³½´Ù. ¿Ü¼º±â-ü°Ý-¼ºÂ¡ µîÀǠƯ¡ÀûÀΠÁõ¼¼·Î º¼ ¶§¿¡ ¿ÏÀüÇÑ ³²¼ºÀÌ °áÈ¥ÇÏ¿© ¼º»ýȰ±îÁö ÇÏ¿´À¸³ª, ÀÚ½ÄÀÌ ¾øÀÚ ºÎºÎ°¡ ÇÔ²² º´¿øÀ» Ã£¾Æ°¡¼­ ¿°»öü¸¦ °Ë»çÇØ º¸°í ³²ÀÚ¿¡°Ô ÀÌ ÁõÈıºÀÌ ÀÖÀ½À» ¾Ë°Ô µÇ´Â °æ¿ì°¡ ¸¹´Ù. ÀÌ ¹Û¿¡ ¼ºÀÎÀÌ µÇ¾î ³ªÅ¸³ª´Â ÁÖ¿ä Áõ¼¼¸¦ µé¸é, ÀÛÀº°íȯ, ¿©¼ºÇü À¯¹æÁõ, ¹«Á¤ÀÚÁõ, ºÒÀÓ, ¿äÁß °í³ªµµÆ®·ÎÇÉÀÇ »ó½Â, Áö´É ÀúÇÏ µîÀÌ´Ù. Ä¡·á´Â 2Â÷ ¼ºÂ¡ÀÇ ÃËÁøÀ» À§ÇÏ¿© È£¸£¸ó¿ä¹ý¿¡ ÀÇÇÑ ³²¼ºÈ­¸¦ ½ÃµµÇÑ´Ù.
¿µ¹® fetal alcohol syndrome ÇÑ±Û Å¾ƾËÄÚ¿ÃÁõÈıº
¼³¸í   
  ÀӽűⰣ Áß ¸¸¼ºÀûÀ¸·Î ¾ËÄÚ¿ÃÀ» ¼·ÃëÇÑ ¿©ÀÚ¿¡°Ô¼­ Å¾ ¿µ¾Æ¿¡°Ô ³ªÅ¸³ª´Â ÇüŹ߻ýÀÇ ÀÌ»óÀ» ³ªÅ¸³»´Â ÁõÈıºÀ¸·Î¼­ À§ÅλÀ¹ßÀ°ºÎÀü, ¾Õ¸Ó¸®¿Í ¾Æ·¡ÅÎÀÇ µ¹Ãâ, ÂªÀº°Ë¿­, ÀÛÀº¾È±¸Áõ, ´«±¸¼®ÁÖ¸§, ½ÉÇÑ ¼ºÀåÁö¿¬, Á¤½ÅÁöü µîÀ» ³ªÅ¸³½´Ù.
¿µ¹® Horner syndrome ÇÑ±Û È£¸£³ÊÁõÈıº
¼³¸í   
  ±³°¨½Å°æ°æ·ÎÀÇ Àå¾Ö·Î »ý±â´Â º´ÀÌ´Ù. ±³°¨½Å°æÀº ÀÚÀ²½Å°æÀÇ Çϳª·Î ¿Â¸ö¿¡ ºÐÆ÷¸¦ ÇÑ´Ù. Æ¯È÷ ¾ó±¼ÂÊ¿¡´Â ´«²¨ÇÃÀ» ¿Ã¸®´Â ±ÙÀ°°ú ¶¡»ù¿¡ ºÐÆ÷Çϰí ÀÖ´Ù. À̿͠°°Àº ±³°¨½Å°æÀÇ ÀÛ¿ëÀ¸·Î ´«²¨Ç®À» Á¤»óÀûÀ¸·Î ¿Ã¸®°í ¾ó±¼¿¡ ¶¡ÀÌ ³ª¿À°Ô µÈ´Ù. ±× ¿Ü¿¡µµ ´«ÀÇ ºûÀÇ ¾çÀ» Á¶ÀýÇϴ ȫ並 ¼öÃà½Ã۴ ±ÙÀ°¿¡ ºÐÆ÷ÇØ¼­ ±× ÀÛ¿ëÀ¸·Î ´«ÀǠȫä°¡ ¼öÃàÇÏ¿© µ¿°øÀÌ Ä¿Áö°Ô µÈ´Ù. ±³°¨½Å°æÀº ±× ±â¿øÀÌ ´ë³ú¼Ó¿¡ Á¸ÀçÇϴ ½Ã»óÇϺζó´Â °÷À̰í À̰÷¿¡¼­ ½ÃÀÛÇÑ ±³°¨½Å°æÀº Ã´¼ö¸¦ Å¸°í ³»·Á¿Í¼­ ¸ñºÎÀ§¿¡¼­ Ã´¼ö¸¦ ºüÁ®³ª¿Í¼­ ±³°¨½Å°æÀ» Áٱ⸦ Çü¼ºÇÏ¿© ´Ù½Ã ³ú·Î °¡´Â Ç÷°üÀ» µû¶ó¼­ ¾ó±¼ÂÊÀ¸·Î °¡°ÔµÈ´Ù. ¸¸¾à ÀÌ ±³°¨½Å°æÀÇ ÁÖÇàºÎÀ§¿¡ º´º¯ÀÌ »ý±â¸é ±×ÂÊÀÇ ¾ó±¼¿¡ ±³°¨½Å°æÀÌ Â÷´ÜµÇ¹Ç·Î º´ÅÍÂÊÀÇ ´«ÀÇ ´«²¨Ç®ÃÄÁü, Ãൿ ±×¸®°í º´º¯Ãø ¾ó±¼ºÎÀÇ ¶¡ÀÌ ³ªÁö ¾Ê´Â °Í µîÀÇ Áõ»óÀ» ³ªÅ¸³ª°Ô µÈ´Ù. ÀÌ·± Çö»óÀ» È£¸£³ÊÁõÈıºÀ̶ó°í ÇÑ´Ù. À̰ÍÀº ¿©·¯ °¡Áö º´¿¡¼­ ³ªÅ¸³¯ ¼ö°¡ Àִµ¥ ³ú³ª Ã´¼öÀÇ ÁúȯÁß¿¡¼­ ÀÌ ±³°¨½Å°æ·Î¸¦ ¾Ð¹ÚÇϰųª Ä§¹üÇϴ º´¿¡¼­ »ý±æ ¼öµµ ÀÖÀ¸¸ç, ¶Ç´Â Æó¾ÏÀ̠ô¼ö¿¡¼­ ºüÁ®³ª¿Í ¸ñºÎºÐ¿¡¼­ ÀÌ·é ±³°¨½Å°æÀÇ Áٱ⸦ ´©¸¦ °æ¿ì¿¡µµ »ý±æ ¼öµµ ÀÖ´Ù.
¿µ¹® respiratory distress syndrome(RDS) ÇÑ±Û È£Èí°ï¶õÁõÈıº
¼³¸í   
  ÆóÆ÷¿Í Æó¸ð¼¼Ç÷°ü »çÀÌ¿¡ ºÎÁ¾À¸·Î ÀÎÇÑ È®»ê´É °¨¼Ò·Î È£Èí°ï¶õ°ú Ã»»öÁõÀ» º¸À̴ »óÅ·Π°¨¿°, ¼ö¼ú, ¿Ü»ó µî ¸ðµç Á¾·ùÀÇ ½ºÆ®·¹½º»óȲ¿¡¼­ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. Ä¡·á´Â ¼±Çà ¿äÀÎÀÇ ±³Á¤°ú ÀûÀýÇÑ Ç÷¾×³» »ê¼Ò³óµµ À¯ÁöÀÌ´Ù.
¿µ¹® acquired immunodeficiency syndrome ÇÑ±Û ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
¼³¸í   
  Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV)¿¡ ÀÇÇÏ¿© ¸é¿ª ¼¼Æ÷°¡ ÆÄ±«µÊÀ¸·Î½á ÀÎüÀÇ ¸é¿ª´É·ÂÀÌ ±Øµµ·Î ÀúÇϵǾ´¿øÃ¼¿¡ ´ëÇÏ¿© ¹«¹æºñ »óÅ¿¡ À̸£´Â º´. ¿¡ÀÌÁî ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â¸ç, 1981³â ¹Ì±¹¿¡¼­ Ã³À½ º¸°íµÇ¾ú´Ù. ÃÖÃÊ °¨¿°À¸·ÎºÎÅÍ Áõ»óÀÌ ³ªÅ¸³ª±â±îÁö´Â Æò±Õ 10³â Á¤µµ °É¸®¸ç »ç¸Á·üÀÌ ´ë´ÜÈ÷ ³ô´Ù. ¼ºÀû Á¢ÃË, ¿À¿° ÁÖ»ç±â »ç¿ë, ¿À¿° Ç÷¾× ¹× Ç÷¾× Á¦Á¦ »ç¿ë, ¿¡ÀÌÁî »ê¸ð·ÎºÎÅÍ ¼öÁ÷°¨¿° µûÀ§¿¡ ÀÇÇÏ¿© °¨¿°µÈ´Ù. °¨¿° ÈÄ Àϰú¼ºÀ¸·Î °¨±â¿Í °°Àº Áõ»óÀ» º¸À̸砹ÙÀÌ·¯½ºÇ÷ÁõÀ¸·Î µÇÁö¸¸ ¹ÙÀÌ·¯½º´Â °¨¼ÒµÇ°í 6~8ÁÖ ÈÄ¿¡´Â Ç×ü°¡ ¾ç¼ºÀ¸·Î µÈ´Ù. 6~10³â Á¤µµÀÇ ¹«ÁõÈļº º¸±Õ±â°£À» Áö³ª¼­ ¿¡ÀÌÁî°ü·ÃÁõÈıº(AIDS related syndrome)À¸·Î µÈ´Ù. ÀúÇ×·ÂÀÇ °¨¼Ò, ¸²ÇÁÀýºñ´ë, Ã¼Áß°¨¼Ò, ¹ß¿­, ¸¸¼º¼³»ç°¡ À̾îÁø´Ù. ±× ÈÄ ¿¡ÀÌÁî·Î µÇ¸ç, ÆóÆ÷ÀÚÃæÆó·Å µîÀÇ ¿øÃ溴, Ä­µð´Ù µîÀÇ Áø±ÕÁõ, Ç츣Æä½º¹ÙÀÌ·¯½º±º µîÀÇ ±âȸ°¨¿°ÀÌ À̾îÁø´Ù. ¶ÇÇÑ Ä«Æ÷½ÃÀ°Á¾, ¸²ÇÁÁ¾ µîÀ» º´¹ßÇØ¼­ »ç¸ÁÇÑ´Ù. ¹ÙÀÌ·¯½ºÀÇ ³úÁ¶Á÷³» Áõ½ÄÀ¸·Î Ä¡¸Å¸¦ ÀÏÀ¸Å³ ¼öµµ ÀÖ´Ù. HIV-1Àº 10³â°£¿¡ »ç¸Á·üÀÌ 90%, HIV-2´Â 10%ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • specific immunity
    ƯÀ̸鿪
  • sterilizing immunity
    ºÒÀӸ鿪
  • anginal syndrome
    Çù½ÉÁõÁõÈıº
  • anterior interosseous nerve syndrome
    ¾Õ»À»çÀ̽ŰæÁõÈıº, Àü¹æ°ñ°£½Å°æÁõÈıº
  • anterior spinal artery syndrome
    ¾Õô¼öµ¿¸ÆÁõÈıº
  • anterior tibial compartment syndrome
    Á¾¾Æ¸®¾ÕÄ­ÁõÈıº, ¾ÕÁ¤°­±¸È¹ÁõÈıº
  • anxiety syndrome
    ºÒ¾ÈÁõÈıº
  • aortic arch syndrome
    ´ëµ¿¸ÆÈ°ÁõÈıº, ´ëµ¿¸Æ±ÃÁõÈıº
  • apallic syndrome
    ´ë³ú°ÑÁú»ó½ÇÁõÈıº, ´ë³úÇÇÁú»ó½ÇÁõÈıº
  • Apert syndrome
    ¾ÆÆä¸£ÁõÈıº
  • Asherman¡¯s syndrome
    ¾Æ¼Å¸¸ÁõÈıº
  • auriculotemporal syndrome
    ±Ó¹ÙÄû°üÀÚÁõÈıº, À̰³ÃøµÎ½Å°æÁõÈıº
  • Ayerza syndrome
    ¾Æ¿¹¸£»çÁõÈıº
  • acquired immunodeficiency syndrome
    ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • acute brain syndrome
    ±Þ¼º³úÁõÈıº
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • tarsal tunnel syndrome
    ¹ß¸ñ±¼ÁõÈıº, Á·±Ù°üÁõÈıº
  • testicular feminization syndrome
    °íȯ¿©¼ºÈ­ÁõÈıº
  • thoracic outlet syndrome
    °¡½¿¹®ÁõÈıº, Èä°ûÃⱸÁõÈıº
  • Turner's syndrome
    ÅͳÊÁõÈıº
  • withdrawal syndrome
    ±Ý´ÜÁõÈıº
  • Wolff-Parkinson White syndrome
    ¿ùÇÁÆÄŲ½¼È­ÀÌÆ®ÁõÈıº
  • WPW syndrome
    (¢¡Woff Parkinson White syndrome) ¿ùÇÁÆÄŲ½¼È­ÀÌÆ®ÁõÈıº
  • X syndrome
    ÁõÈıº¿¢½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • humoral immunity
    ü¾×¸é¿ª
  • immunity
    ¸é¿ª
  • infection immunity
    °¨¿°¸é¿ª
  • innate immunity
    ¼±Ãµ¸é¿ª
  • local immunity
    ±¹¼Ò¸é¿ª
  • maternal immunity
    ¸ð¼º¸é¿ª
  • native immunity
    (¢¡innate immunity) ¼±Ãµ¸é¿ª
  • natural immunity
    ÀÚ¿¬¸é¿ª
  • nonspecific immunity
    ºñƯÀ̸鿪
  • opsonic immunity
    ¿É¼Ò´Ñ¸é¿ª
  • passive immunity
    ¼öµ¿¸é¿ª
  • permanent immunity
    ¿µ±¸¸é¿ª
  • protective immunity
    ¹æ¾î¸é¿ª
  • racial immunity
    ÀÎÁ¾¸é¿ª
  • relative immunity
    »ó´ë¸é¿ª
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • alimentary deficiency =dietary d.
    ½Ä»çºÎÁ·, ¿µ¾çºÎÁ·.
  • anemia iron deficiency
    ö°áÇ̼º ºóÇ÷.
  • anemia,folate deficiency
    ¿±»ê°áÇÌ(ç¨ß«ÌÀù¹)
  • anterior pituitary deficiency
    ³úÇϼöüÀü¿±±â´ÉºÎÀü(Áõ)
  • anterior pituitary deficiency
    ÇϼöüÀü¿±±â´ÉºÎÀü(Áõ).
  • antitrypsin deficiency
    Çׯ®¸³½Å°áÇÌ
  • apolipoprotein C-Il deficiency
    ¾ÆÆ÷Áö´Ü¹é C-II °áÇÌ
  • apolipoprotein b, deficiency
    ¾ÆÆ÷¸®Æ÷´Ü¹éB°áÇÌÁõ(¡­Ó±ÛÜ¡­ÌÀù¹ñø)
  • arylsulfatase a deficiency
    ¾Æ¸±¼³ÆÄŸÁ¦ A °áÇÌÁõ(¡­ÌÀù¹ñø)
  • aspartylglycosamine amide hydrolase, deficiency
    Aspartylglycosamine amide hydrolase°áÇÌ(¡­ÌÀù¹)
  • functional deficiency
    ±â´É°áÇÌ
  • g6pd deficiency
    G6PD(Æ÷µµ´ç-6-Àλ꿰 Å»¼ö¼ÒÈ¿¼Ò) °áÇÌÁõ
  • galactosidase, alpha-galactosidase a, deficiency
    #NAME?
  • glucocerebrosidase deficiency
    ±Û·çÄÚ¼¼·¹ºê·Î½Ãµ¥À̽º °áÇÌÁõ
  • glucose 6 phosphatase deficiency hepa
    ±Û·çÄÚ¿À½º-6 -ÀÎ»ê °áÇ̰£½ÅÇü´ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹).
  • adoptive immunity
    ÀÔ¾ç¸é¿ª(¡­Øóæ¹).
  • adoptive immunity
    ÀÔ¾ç¸é¿ª(¡­Øóæ¹).
  • adoptive immunity
    ÀÔ¾ç¸é¿ª(¡­Øóæ¹).
  • antibacterial immunity
    Çױո鿪(¡­Øóæ¹).
  • antibody-mediated immunity
    Ç×ü¸Å°³ ¸é¿ª
  • antimicrobial immunity
    Çױո鿪(¡­Øóæ¹).
  • antitoxic immunity
    Ç×µ¶(¼Ò)¼º ¸é¿ª(ù÷Ô¸áÈàõØóæ¹).
  • antitumor immunity
    Ç×Á¾¾ç(¼º) ¸é¿ª(¡­Øóæ¹).
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(¡­Øóæ¹).
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(~Øóæ¹)
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª.
  • athreptic immunity
    ¹«¿µ¾ç¼º ¸é¿ª.
  • cell mediated immunity
    ¼¼Æ÷¼º¸é¿ª.
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª(á¬øàØÚË¿Øóæ¹)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ADCC cell Antibody Dependent Cellular(= Cell-Mediated) Cytotoxicity cell
ECF   1) Eosinophilic Chemotatic Factors
  2) Extra-Cellular Fluid; ¼¼Æ÷ ¿Ü¾×
HCC Hepato-Cellular Cacinoma
HCCa Hepato-Cellular Cacinoma
ICAMs Inter-Cellular Adhesion Molecules
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CRABP-I Cellular retinoic acid binding protein I
CRABP II Cellular retinoic acid binding protein II
CRBP II Cellular retinol binding protein II
CRBP(II) Cellular retinol-binding protein type II
ECM Extra Cellular Matrix
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • factor XI deficiency
    Á¦11ÀÎÀÚ °áÇÌ
    ÀÌ ÀÎÀÚ°¡ ºÎÁ·µÇ¸é Ç÷¿ìº´ C³ª Rosenthal ÁõÈıºÀ¸·Î ºÒ¸®´Â Àü½Å¼º Ç÷¾× ÀÀ°í Àå¾Ö¸¦ ÀÏÀ¸Å°´Âµ¥ °íÀüÀû Ç÷¿ìº´°ú À¯»çÇÏ´Ù.
  • folate deficiency anemia
    ¿±»ê °áÇ̼º ºóÇ÷
  • folic acid deficiency anemia
    ¿±»ê °áÆð¼º ºóÇ÷
  • fructokinase deficiency
    ÇÁÁ¦ °áÇÌ
  • hexokinase deficiency
    Çí¼ÒŰ³ªÁ¦ °áÇÌ
  • immune deficiency disease
    ¸é¿ª °áÇÌ Áúȯ, ¸é¿ª °áÇ̺´
    ¸é¿ª °èÅëÀ» ±¸¼ºÇÏ´Â ¿ä¼ÒÀÇ ±â´É Àå¾Ö¿¡ ÀÇÇÏ¿© ÃÊ·¡µÇ´Â Áúȯ ±º.
  • immunological deficiency state
    ¸é¿ª °áÇÌ »óÅÂ
  • iron deficiency anemia
    ö °áÇ̼º ºóÇ÷
    1. Àú»ö¼Ò¼º, ¼Ò±¸¼º ÀûÇ÷±¸¼º ºóÇ÷ÀÇ ´ëÇ¥Àû Áúȯ. öÀÇ °áÇÌ¿¡ ÀÇÇÏ¿© Ç÷»ö¼ÒÀÇ »ý¼ºÀÌ ÃæºÐÈ÷ ÇàÇÏ¿©ÁöÁö ¾Ê±â ¶§¹®¿¡ ÀûÇ÷±¸ ¼öº¸´Ùµµ Ç÷»ö¼Ò ³óµµ°¡ ÇöÀúÇÏ°Ô °¨¼ÒÇÑ´Ù. 2. ö ÀúÀå·®ÀÇ ÀúÇÏ, °áÇÌ, Ç÷û ö ³óµµÀÇ ÀúÇÏ, transferrin¾ç »ó½Â, transferrin Æ÷È­µµÀÇ ÀúÇÏ, Àú»ö¼Ò¼º ´ëÀûÇ÷±¸¸¦ Ư¡À¸·Î ÇÏ´Â ºóÇ÷.
  • isolated T-cell deficiency
    T ¼¼Æ÷ °áÇÌ
  • lactase deficiency
    ¶ôŸÁ¦ °áÇÌ
  • mental deficiency
    Áö´É ¹Ú¾à, Áö´É ¹Ú¾àÁõ, Á¤½Å ¹Ú¾àÁõ
    ¿©·¯ °¡Áö ¿øÀο¡ ÀÇÇØ¼­ Áö´É ¹ß´ÞÀÌ Æò±Õº¸´Ù ³·°í Á¤½ÅÀû, ½ÅüÀû Àå¾Ö·Î ÀÎÇØ »çȸ »ýȰ¿¡ ´ëÇÑ ÀûÀÀÀÌ °ï¶õÇÑ »óÅÂ. Á¤½Å Áöü¶ó°íµµ ÇÑ´Ù. Çö´ë ÀÇÇп¡¼­´Â ÁøÇ༺ ¸¶ºñ¿¡ ÀÇÇÑ Ä¡¸Å³ª ÀϽÃÀûÀÎ Á¤½Å ±â´ÉÀÇ ÅðÇà°ú ±¸º°ÇÏ¿© Ç×±¸ÀûÀÎ Áöü »óŸ¦ ÀǹÌÇÑ´Ù. ¶ÇÇÑ ÀÏ¹Ý Áö´ÉÀÇ °áÇÔ¸¸ÀÌ ¾Æ´Ï¶ó '»çȸ »ýȰ¿¡¼­ÀÇ ½ÇõÀû Áö´É'À̶ó ºÎ¸¦ ¸¸ÇÑ Ãø¸é¿¡µµ ÁÖ¸ñÇÏ°Ô µÇ¸é¼­ Á¤½Å ¹Ú¾àÀÇ ºÐ·ù´Â »çȸÀÇ ÀûÀÀµµ¿Í »çȸÀû »ýȰ ´É·Â Á¤µµ¸¦ ¹èÇÕ½ÃŰ°Ô µÇ¾ú´Ù.
  • mineral deficiency
    ¹«±âÁú °áÇÌ, ¹«±âÁú °áÇÌÁõ
  • myeloperoxidase deficiency
    ¸¶ÀÌ¿¤·Î ÆÛ·Ï½Ãµ¥À̽º °áÇÌÁõ
    »ó¿°»öü¼º ¿­¼º ÇüÁú·Î À¯ÀüµÇ¸ç, Áß¼º±¸¿Í ´Ü±¸ÀÇ È£¾ÆÁÖ¸£¼º °ú¸³ ³»¿¡ MPO°¡ ÀüÇô ¾ø´Ù.
  • myoadenylate deaminase deficiency
    ¸¶ÀÌ¿À ¾Æµ¥´Ò·¹ÀÌÆ® µð¾Æ¹Ì³×À̽º °áÇÌÁõ
  • nutrition deficiency
    ¿µ¾ç °áÇÌÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
infection immunity The paradoxical immune status in which resistance to reinfection coincides with the persistence of the original infection.
Synonym: concomitant immunity.
(05 Mar 2000)
innate immunity This includes local barriers to infection such as skin, stomach acid, mucous, the cough reflex, enzymes in tears and saliva and skin oils.
(27 Sep 1997)
local immunity A natural or acquired immunity to certain infectious agents, as manifested by an organ or a tissue, as a whole or in part.
(05 Mar 2000)
adult lactase deficiency Onset of lactase deficiency, with resulting milk intolerance and malabsorption, in adulthood. Inherited forms may not be manifested until adulthood; any process that damages the intestinal lining cells can cause lactase deficiency in adults.
(05 Mar 2000)
alpha-1 antitrypsin deficiency <chest medicine> Deficiency of the protease inhibitor alpha-1 antitrypsin, leads primarily to degradation of elastin of the alveolar walls, as well as other structural proteins of a variety of tissues.
The lack of this protein leads to damage of various organs, but mainly to the lung and liver.
symptoms may become apparent at a very early age or in adulthood, manifesting either as shortness of breath or liver related symptoms (jaundice, fatigue, fluid in the abdomen, mental changes, or gastrointestinal bleeding). There are several options for treatment of the lung disease, including replacement of the missing protein. Treatment of the liver disease is a well-timed liver transplant
(12 Dec 1998)
alpha-1-proteinase deficiency Absence of a serum proteinase inhibitor that may cause nodular non-suppurative panniculitis.
(05 Mar 2000)
alpha-antitrypsin deficiency <enzyme> A specific enzyme (alpha 1 antitrypsinase) that when absent genetically can result in panacinar emphysema (lung disease) and liver disease.
There is no specific treatment for this condition other than supportive care for the liver and lung complications.
Medications such as alpha-1proteinase inhibitor is given regularly to these patients.
Incidence: approximately 1 in 10,000.
(02 Jan 1998)
anaemia, iron deficiency Deficiency of iron results in anaemia because iron is necessary to make haemoglobin, the key molecule in red blood cells responsible for the transport of oxygen. In iron deficiency anaemia, the red cells are unusally small (microcytic) and pale (hypochromic). Characteristic features of iron deficiency anaemia in children include failure to thrive (grow) and increased infections. The treatment of iron deficiency anaemia, whether it be in children or adults, is with iron and iron-containing foods. Food sources of iron include meat, poultry, eggs, vegetables and cereals (especially those fortified with iron). According to the National Academy of Sciences, the Recommended Dietary Allowances of iron are 15 milligrams per day for women and 10 milligrams per day for men.
Anaemia characterised by low or absent iron stores, low serum iron concentration, elevated free erythrocyte porphorin, low transferrin saturation, elevated transferrin, low serum ferritin, low haemoglobin concentration or haematocrit, and hypochromic microcytic red blood cells. Symptoms may include pallor, angular stomatitis and other oral lesions, gastrointestinal complaints, retinal haemorrhages and exudates, and thinning and brittleness of the nails. Among the causes of iron-deficiency anaemia are inadequate iron intake, impaired iron absorption, increased blood loss and increased requirements such as infancy, pregnancy, and lactation.
(12 Dec 1998)
antibody deficiency disease <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
antitrypsin deficiency Deficiency of a1-antitrypsin, a glycoprotein of the postalbumin region of human serum. Many forms are known which may be moderate (40 to 60% of normal activity) or severe (less than 10% of normal), all autosomal dominant; the severe form is often associated with familial emphysema or hepatic cirrhosis.
(05 Mar 2000)
arch length deficiency The difference between the available circumference of the dental arch and that required to accommodate the succedaneous teeth in proper alignment.
(05 Mar 2000)
arginase deficiency <biochemistry> Arginase is the fifth enzyme of the urea cycle and catalyses the hydrolysis of arginine to ornithine and urea as the final step in the detoxification of ammonia.
Deficiency of the enzyme results in hyperargininaemia and episodic hyperammonaemia, leading to moderate to severe mental retardation and spasticity. at least two isozymes of arginase exist in man. AI (the enzyme deficient in the disorder) is cytosolic and found primarily in liver and red blood cells, whereas AII is mitochondrial and found predominantly in kidney but also to a lesser extent in liver, brain, and other tissues.
While AII activity appears to be induced in AI deficiency, it is only partially effective in maintaining urea cycle function. The normal in vivo function of AII is unclear.
Arginase deficiency is diagnosed by observing high arginine concentrations on either qualitative or quantitative plasma or urine amino acid analysis. The diagnosis is confirmed by finding markedly decreased or absent arginase activity in an isotopic red blood cell enzymatic assay. The AI gene has been cloned, sequenced, and localised to human chromosome band 6q23.
(17 Dec 1997)
ascorbic acid deficiency A condition due to a dietary deficiency of ascorbic acid (vitamin c), characterised by malaise, lethargy, and weakness. As the disease progresses, joints, muscles, and subcutaneous tissues may become the sites of haemorrhage. Ascorbic acid deficiency frequently develops into scurvy in young children fed unsupplemented cow's milk exclusively during their first year. It develops also commonly in chronic alcoholism. (cecil textbook of medicine, 19th ed, p1177)
(12 Dec 1998)
beta-d-glucuronidase deficiency A rare deficiency of beta-d-glucuronidase; an autosomal recessive disorder with several allelic forms, characterised by abnormal mucopolysaccharide metabolism leading to progressive mental deterioration, splenic and hepatic enlargement, and dysostosis multiplex.
Synonym: mucopolysaccharidase.
(05 Mar 2000)
brancher deficiency glycogenosis Type of glycogen storage disease, due to deficiency of amylo-1,4-1,6-transglucosidase (brancher enzyme).
Synonym: brancher deficiency glycogenosis, debrancher deficiency.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á